Prices delayed by at least 15 minutes | Print
Shield Therapeutics PLC (STX)
ORD 1.5PThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Company profile
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
Address
Northern Design Centre Studio 6
3rd Floor, Baltic Business Quarter
Newcastle
GBR
NE8 3DF
Telephone
+44 1915118500
Forecast key dates
| Name | Key Date |
|---|---|
| Shield Therapeutics PLC Fourth Quarter Earnings Results for 2025 | 2026-04-24T00:00:00 |
| Shield Therapeutics PLC Second Quarter Earnings Results for 2025 | 2025-09-04T00:00:00 |
| Shield Therapeutics PLC Annual General Meeting for 2024 | 2025-05-22T14:00:00 |
| Shield Therapeutics PLC Annual Report for 2024 | 2025-05-09T00:00:00 |
| Shield Therapeutics PLC Fourth Quarter Earnings Results for 2024 | 2025-04-24T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Shield Therapeutics PLC Fourth Quarter Earnings Results for 2024 | 2025-04-24T00:00:00 |
| Shield Therapeutics PLC Second Quarter Earnings Results for 2024 | 2024-09-04T00:00:00 |
| Shield Therapeutics PLC Annual General Meeting for 2023 | 2024-06-20T14:00:00 |
| Shield Therapeutics PLC Annual Report for 2023 | 2024-05-10T00:00:00 |
| Shield Therapeutics PLC Fourth Quarter Earnings Results for 2023 | 2024-04-30T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.